DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan (OXA-07)

Single Centre Open-label, Non-randomised, 3-treatment, 2-period, Pharmacokinetic Drug Interaction Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan in Healthy Male Participants

To assess Drug drug interactions between Acoziborole and Dextromethorphan and Midazolam in healthy male volunteers.

Study Overview

• Status: Completed
• Conditions: Trypanosomiasis, African
• Intervention / Treatment: Drug: Midazolam; Drug: Dextromethorphan; Drug: Acoziborole

Detailed Description

An in silico PB-PK model was developed within the simCYP software and qualified for acoziborole. This study suggested strong interactions with sensitive index substrates of CYP2D6 and CYP3A4.To validate these PB-PK model results, an open-label, non-randomised, three-treatment, one-sequence, two successive periods study with at least 3-day washout between periods was chosen to evaluate clinically the potential impact of acoziborole on plasma exposure of two different sensitive CYP substrates, DXM for CYP2D6 and midazolam for CYP3A4.

Acoziborole will be administered as a single dose, due to the long t1/2 of 360 h in healthy participants.

The SimCYP simulations showed that the best compromise to maximize the CYP2D6 inhibition and minimize the CYP3A4 induction is when DXM is given 24 to 60 h after acoziborole administration. Therefore, dextromethorphan will be given on Day 1 (in Period 1, without acoziborole) and on Day 14 in Period 2 i.e. 2 days following oral administration of acoziborole.

Based on the PB-PK simulations, the interaction between acoziborole and midazolam should be maximal around Day 8 (due to the activity CYP3A4) following acoziborole administration and sustained for several weeks after. Thus, midazolam will be given on Day 8 (in Period 1 without acoziborole) and on Day 21 in Period 2 i.e. 9 days following oral single administration of acoziborole.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 1

Contacts and Locations

Study Locations

• Malaysia
  • Kuala Lumpur, Malaysia
    • Clinical Research Center (CRC) Ampang Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy males.
• Have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures..
• Age 18 to 55 (inclusive) years of age at the time of signing informed consent.
• Body mass index (BMI) of 18.0 to 30.0 kg/m2 as measured at screening.
• Body weight not less than 50 kg.
• Non-smokers (defined as has not used nicotine-containing products including e-cigarette for at least 3 months prior to the first dose as confirmed by cotinine test).
• Must be willing and able to communicate and participate in the whole study.
• Normal blood pressure (BP): Systolic BP (SBP) between 90 and 140 mmHg (inclusive), diastolic BP (DBP) between 45 and 90 mmHg (inclusive), measured after 10 min rest in supine position at screening and first admission (Day -1).
• A resting heart rate (HR) between 45 and 90 bpm (inclusive), measured after 10 min rest in supine position at screening and first admission (Day -1).
• ECG recording without clinically significant abnormality, including Fridericia's corrected interval between Q and T waves (QTcF) measure of ≤450 msec at screening and first admission (Day -1).
• Participants must be able to swallow multiple capsules.

Exclusion Criteria:

• Have participated in an investigational trial involving administration of any investigational compound within 90 days prior to the study dosing or 5-times the half-life of the drug tested in the previous clinical trial, whichever is longer (time calculated relative to the last dose in the previous clinical trial).
• History of any drug or alcohol abuse in the past 2 years.
• Regular alcohol consumption >14 units per week and (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type) as confirmed by a positive alcohol breath test at screening or any on admission to the CRW.
• Participants who do not have suitable veins for multiple venepunctures/cannulations as assessed by the Investigator or delegate at screening.
• Clinically significant abnormal clinical chemistry, haematology, urinalysis, or clinically significant abnormal physical examination findings as judged by the Investigator.
• Abnormal renal function (estimate glomerular filtration rate [eGFR] <90 mL/min).
• Confirmed positive drugs of abuse urine test result (including but not limited to, amphetamines, tetrahydrocannabinol, morphine, methamphetamine, ketamine and benzodiazepines) and at any time during the study.
• Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results.
• Positive COVID test at screening and at admission of hospitalisation.
• COVID-19 full vaccination to be received less than 21 days before Day 1, or start of vaccination, or second dose or booster of vaccination planned during the study period.
• Clinically significant medical condition and/or abnormal laboratory results that could, in the opinion of the Investigator, jeopardize the participant's safety or participation in the study.
• Known serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients in the past.
• Presence or history of clinically significant allergy requiring treatment (including asthma, urticaria, clinically significant allergic rash or other severe allergic diathesis), as judged by the Investigator. Hay fever is allowed unless it is active.
• Donation or loss of greater than 400 mL of blood within the previous 3 months or more than 100 mL within 30 days before signing informed consent form (ICF) to this trial.
• Participants who are taking any prescribed drug in the 30 days before screening or require regular use of any prescription medication during the study.
• Participants who have taken, any OTC medications, including vitamins, analgesics or antacids, herbal remedies, St. John's wort or diet complements (plants and vitamins that may be used for e.g. weight control or improve digestion or for "detox"... e.g., found in the composition extracts of ginkgo biloba, aesculus, cassia, harpagophytum, curcuma, elderberry, Vitis vinifera, cypress (Cupressus sempervirens)) in the 30 days before investigational medicinal product (IMP) administration. Exceptions may apply on a case-by-case basis, if considered not to interfere with the objectives of the study, as determined by the Principal Investigator (PI).
• Use of enzyme-altering drugs (e.g. barbiturates, phenothiazines, cimetidine) within 30 days or 5 half-lives, whichever is longer, of study Day 1.
• Use of products containing quinine (e.g., tonic water), grapefruit products, pomelo products, Seville orange products, supplements containing citrus aurantium and bitter orange in the 30 days prior to study Day 1.
• CYP2D6 poor metabolizers, based on genotyping of DNA from blood samples.
• Surgery within 12 weeks prior to screening, with the exception of appendectomy or at the discretion of the Investigator for minor surgery.
• Any surgery (e.g. gastric bypass) or medical condition that may affect absorption of orally administered drugs.
• Failure to satisfy the Investigator of fitness to participate for any other reason.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Dextromethorphan and Midazolam; Drug drug interaction Dextromethorphan and Midazolam administrations; Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1; Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8	Drug: Midazolam; • Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8 Period 2: Single oral dose of 5 mg administered on Day 21; Drug: Dextromethorphan; • Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1 Period 2: Single oral dose of 15 mg administered on Day 14
Other: Acoziborole, Dextromethorphan and Midazolam; Drug drug interaction Acoziborole, Dextromethorphan and Midazolam administrations; Acoziborole 960 mg (three tablets of 320 mg) for oral route in fasted condition Period 2: single oral administration on Day 12; Dextromethorphan 15 mg syrup in fasted condition Period 2: Single oral dose of 15 mg administered on Day 14; Midazolam 5 mg syrup in fasted condition Period 2: Single oral dose of 5 mg administered on Day 21	Drug: Midazolam; • Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8 Period 2: Single oral dose of 5 mg administered on Day 21; Drug: Dextromethorphan; • Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1 Period 2: Single oral dose of 15 mg administered on Day 14; Drug: Acoziborole; Acoziborole 960 mg (three tablets of 320 mg) for oral route in fasted condition Period 2: single oral administration on Day 12

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess the effect of single dose of acoziborole on pharmacokinetics (PK) parameters (Cmax) of midazolam as a probe substrate for CYP3A4 (induction)	Midazolam Cmax, plasma concentration	Up to 72 hours post drug administration
To assess the effect of single dose of acoziborole on pharmacokinetics (PK) parameters (Cmax) of dextromethorphan as a probe substrate for CYP2D6 (inhibition).	Dextromethorphan Cmax, plasma concentration	Up to 72 hours post drug administration
To assess the effect of single dose of acoziborole on pharmacokinetics (PK) parameters ( AUC0-t) of midazolam as a probe substrate for CYP3A4 (induction)	Midazolam AUC0-t (plasma concentration) of Period 1 and Period 2.	Up to 72 hours post drug administration
To assess the effect of single dose of acoziborole on pharmacokinetics (PK) parameters ( AUC0-t) of dextromethorphan as a probe substrate for CYP2D6 (inhibition).	Dextromethorphan AUC0-t (plasma concentration) of Period 1 and Period 2.	Up to 72 hours post drug administration
To assess the effect of single dose of acoziborole on pharmacokinetics (PK) parameters (AUC0-24) of midazolam as a probe substrate for CYP3A4 (induction)	Midazolam AUC0-24 (plasma concentration) of Period 1 and Period 2	Up to 72 hours post drug administration
To assess the effect of single dose of acoziborole on pharmacokinetics (PK) parameters (AUC0-24) of dextromethorphan as a probe substrate for CYP2D6 (inhibition).	Dextromethorphan AUC0-24 of Period 1 and Period 2.	Up to 72 hours post drug administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the clinical and laboratory safety of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Frequency and cumulative incidence of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) from time of first IMP administration (dextromethorphan on Day 1 in Period 1) to EoS visit.	Up to End of Study Visit, Day 31
To evaluate the clinical safety of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone: Height	Vital signs for safety monitoring: Height (cm)	Baseline
To evaluate the clinical safety of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone: weight	Vital signs for safety monitoring: Weight (Kgs)	Baseline and End of Study (Day 28 to Day 31)
To evaluate the clinical safety of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone: Sistolic and Diastolic BP	Vital signs for safety monitoring: Sistolic BP and Diastolic BP (mmHg)	Up to End of Study (Day 28 to Day 31)
To evaluate the clinical safety of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone: respiratory rate	Vital signs for safety monitoring: respiratory rate (breaths/minute)	Up to End of Study (Day 28 to Day 31)
To evaluate the clinical safety of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone: ear body temperature	Vital signs for safety monitoring: ear body temperature (°C).	Up to End of Study (Day 28 to Day 31)
To evaluate the clinical safety of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone: 12-lead ECG Heart Rate	12-lead electrocardiogram (ECG) Heart Rate for safety monitoring purpose. ECGs for safety purpose will be performed using the internationally recognized 12 leads with devices recorder after 10 min rest in supine position and before any blood draws. ECG will be recorded at a standard paper speed of 25 mm/s and gain of 10 mm/mV. Print-outs for each ECG will include: date, time, initials of the Investigator or its deputy. The ECGs will be performed in 6 × 2 leads during this study. The corresponding source data will consist of the ECG recorder paper print-outs. The ECGs will be read and analysed by the Investigator.	Up to Day 22
To evaluate the clinical safety of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone: 12-lead ECG RR Interval	12-lead electrocardiogram (ECG) RR Interval for safety monitoring purpose. ECGs for safety purpose will be performed using the internationally recognized 12 leads with devices recorder after 10 min rest in supine position and before any blood draws. ECG will be recorded at a standard paper speed of 25 mm/s and gain of 10 mm/mV. Print-outs for each ECG will include: date, time, initials of the Investigator or its deputy. The ECGs will be performed in 6 × 2 leads during this study. The corresponding source data will consist of the ECG recorder paper print-outs. The ECGs will be read and analysed by the Investigator.	Up to Day 22
To evaluate the clinical safety of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone: 12-lead ECG QRS duration	12-lead electrocardiogram (ECG) QRS duration for safety monitoring purpose. ECGs for safety purpose will be performed using the internationally recognized 12 leads with devices recorder after 10 min rest in supine position and before any blood draws. ECG will be recorded at a standard paper speed of 25 mm/s and gain of 10 mm/mV. Print-outs for each ECG will include: date, time, initials of the Investigator or its deputy. The ECGs will be performed in 6 × 2 leads during this study. The corresponding source data will consist of the ECG recorder paper print-outs. The ECGs will be read and analysed by the Investigator.	Up to Day 22
To evaluate the clinical safety of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone: 12-lead ECG QT-interval	12-lead electrocardiogram (ECG) QT-interval for safety monitoring purpose. ECGs for safety purpose will be performed using the internationally recognized 12 leads with devices recorder after 10 min rest in supine position and before any blood draws. ECG will be recorded at a standard paper speed of 25 mm/s and gain of 10 mm/mV. Print-outs for each ECG will include: date, time, initials of the Investigator or its deputy. The ECGs will be performed in 6 × 2 leads during this study. The corresponding source data will consist of the ECG recorder paper print-outs. The ECGs will be read and analysed by the Investigator.	Up to Day 22
To evaluate the clinical safety of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone: 12-lead ECG QTcF-interval	12-lead electrocardiogram (ECG) QTcF-interval for safety monitoring purpose. ECGs for safety purpose will be performed using the internationally recognized 12 leads with devices recorder after 10 min rest in supine position and before any blood draws. ECG will be recorded at a standard paper speed of 25 mm/s and gain of 10 mm/mV. Print-outs for each ECG will include: date, time, initials of the Investigator or its deputy. The ECGs will be performed in 6 × 2 leads during this study. The corresponding source data will consist of the ECG recorder paper print-outs. The ECGs will be read and analysed by the Investigator.	Up to Day 22
To evaluate the clinical safety of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone: 12-lead ECG PR Interval	12-lead electrocardiogram (ECG) PR Interval for safety monitoring purpose. ECGs for safety purpose will be performed using the internationally recognized 12 leads with devices recorder after 10 min rest in supine position and before any blood draws. ECG will be recorded at a standard paper speed of 25 mm/s and gain of 10 mm/mV. Print-outs for each ECG will include: date, time, initials of the Investigator or its deputy. The ECGs will be performed in 6 × 2 leads during this study. The corresponding source data will consist of the ECG recorder paper print-outs. The ECGs will be read and analysed by the Investigator.	Up to Day 22
To evaluate the laboratory safety, Hemoglobin, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, hemoglobin, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, Red blood cell count, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, Red blood cell count, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, hematocrit, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, hematocrit, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, white blood cells count, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, white blood cells count, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, mean corpuscular volume, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, mean corpuscular volume, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, mean corpuscular hemoglobin, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, mean corpuscular hemoglobin, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, red cell distribution width, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, red cell distribution width, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, neutrophils, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, neutrophils, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, lymphocytes, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, lymphocytes, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, monocytes, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, monocytes, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, eosinophils, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, eosinophils, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, basophils, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, basophils, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, platelet count, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, platelet count, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, ALP, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, ALP, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, ALT, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, ALT, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, AST, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, AST, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, GGT, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, GGT, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, CPK, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, CPK, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, total bilirubin, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, total bilirubin, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, direct bilirubin, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, direct bilirubin, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, indirect bilirubin, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, indirect bilirubin, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, total protein, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, total protein, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, albumin, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, albumin, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, creatinine, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, creatinine, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, eGFR, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, eGFR, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, fasting glucose, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, fasting glucose, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, urea, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, urea, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, calcium, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, calcium, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, Na+, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, Na+, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, K+, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, K+, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, Cl-, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, Cl-, from baseline to EoS visit.	Up to Day 22
To evaluate the laboratory safety, bicarbonates, of acoziborole co-administered with midazolam and dextromethorphan as compared to administration of midazolam and dextromethorphan alone.	Laboratory safety assessments, bicarbonates, from baseline to EoS visit.	Up to Day 22
To evaluate the Tmax of midazolam when co-administered with acoziborole.	Time to maximum observed plasma concentration (tmax) for midazolam	Up to Day 22
To evaluate the Tmax of dextromethorphan when co-administered with acoziborole.	Time to maximum observed plasma concentration (tmax) for dextromethorphan.	Up to Day 22
To evaluate the apparent terminal elimination half-life of midazolam when co-administered with acoziborole.	Apparent terminal elimination half-life (t½) for midazolam	Up to Day 22
To evaluate the apparent terminal elimination half-life of dextromethorphan, when co-administered with acoziborole.	Apparent terminal elimination half-life (t½) for dextromethorphan.	Up to Day 22
To evaluate the AUC0-∞ of midazolam when co-administered with acoziborole.	AUC0-∞ for midazolam	Up to Day 22
To evaluate the AUC0-∞ of dextromethorphan when co-administered with acoziborole.	AUC0-∞ for dextromethorphan.	Up to Day 22
To evaluate the Acoziborole plasma concentrations when co-administered with midazolam and dextromethorpharm	Acoziborole plasma concentrations	Up to Day 22
To evaluate the Cmax of midazolam's metabolite, 1'hydroxy-midazolam, when co-administered with acoziborole.	1'-hydroxy-midazolam: Cmax for Period 1 and Period 2.	Up to Day 22
To evaluate the Tmax of midazolam's metabolite, 1'hydroxy-midazolam, when co-administered with acoziborole.	1'-hydroxy-midazolam: tmax for Period 1 and Period 2.	Up to Day 22
To evaluate the AUC0-24 of midazolam's metabolite, 1'hydroxy-midazolam, when co-administered with acoziborole.	1'-hydroxy-midazolam:AUC0-24 for Period 1 and Period 2.	Up to Day 22
To evaluate the AUC0-t of midazolam's metabolite, 1'hydroxy-midazolam, when co-administered with acoziborole.	1'-hydroxy-midazolam: AUC0-t for Period 1 and Period 2.	Up to Day 22
To evaluate the t½ of midazolam's metabolite, 1'hydroxy-midazolam, when co-administered with acoziborole.	1'-hydroxy-midazolam: t½ for Period 1 and Period 2.	Up to Day 22
To evaluate the AUC0-∞ of midazolam's metabolite, 1'hydroxy-midazolam, when co-administered with acoziborole.	1'-hydroxy-midazolam: AUC0-∞ for Period 1 and Period 2.	Up to Day 22
To evaluate the Cmax of dextromethorphan's metabolite, dextrorphan (DXO), when co-administered with acoziborole.	DXO: Cmax for Period 1 and Period 2.	Up to Day 22
To evaluate the Tmax of dextromethorphan's metabolite, dextrorphan (DXO), when co-administered with acoziborole.	DXO: tmax for Period 1 and Period 2.	Up to Day 22
To evaluate the AUC0-24 of dextromethorphan's metabolite, dextrorphan (DXO), when co-administered with acoziborole.	DXO: AUC0-24 for Period 1 and Period 2.	Up to Day 22
To evaluate the AUC0-t of dextromethorphan's metabolite, dextrorphan (DXO), when co-administered with acoziborole.	DXO: AUC0-t for Period 1 and Period 2.	Up to Day 22
To evaluate the t½ of dextromethorphan's metabolite, dextrorphan (DXO), when co-administered with acoziborole.	DXO: t½ for Period 1 and Period 2.	Up to Day 22
To evaluate the AUC0-∞ of dextromethorphan's metabolite, dextrorphan (DXO), when co-administered with acoziborole.	DXO: AUC0-∞ for Period 1 and Period 2.	Up to Day 22

Collaborators and Investigators

• Sponsor: Drugs for Neglected Diseases
• Investigators: Principal Investigator: Sharon Ng Shi Min, Clinical Research Center (CRC) Ampang Hospital

Study record dates

Study Major Dates

• Study Start (Actual): February 9, 2023
• Primary Completion (Actual): May 3, 2023
• Study Completion (Actual): May 3, 2023

Study Registration Dates

• First Submitted: March 5, 2023
• First Submitted That Met QC Criteria: July 7, 2023
• First Posted (Actual): July 17, 2023

Study Record Updates

• Last Update Posted (Actual): July 17, 2023
• Last Update Submitted That Met QC Criteria: July 7, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Vector Borne Diseases; Parasitic Diseases; Protozoan Infections; Euglenozoa Infections; Trypanosomiasis; Trypanosomiasis, African; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Anesthetics, Intravenous; Anesthetics, General; Anesthetics; Excitatory Amino Acid Antagonists; Excitatory Amino Acid Agents; Tranquilizing Agents; Psychotropic Drugs; Hypnotics and Sedatives; Adjuvants, Anesthesia; Anti-Anxiety Agents; GABA Modulators; GABA Agents; Respiratory System Agents; Antitussive Agents; Midazolam; Dextromethorphan
• Other Study ID Numbers: DNDi-OXA-07-HAT

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No